Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • #16
    Originally posted by AllSeq View Post
    After effectively exiting the NGS market in 2013, Roche is making moves to get back into it with their acquisition of Genia for up to $350M ($125 up front and $225 in potential future payments). Read more on our blog.
    Brilliant move or sign of desperation on the part of Roche? After sending $60M+ down the drain with IBM they are now back to the big dance, now with (apparently) murky IP situation. ONT has licensed so much IP on the biochemistry side that it is not clear (to me) how Genia works around that. Judging from the patents that are now published, the sensors themselves are interesting but not terribly unique. The guys know their analog design (duh), but without biochemistry they will go nowhere. Maybe this is what Roche is banking on - take the platform and add their own biochemistry.

    Comment


    • #17
      Originally posted by BBoy View Post
      The guys know their analog design (duh), but without biochemistry they will go nowhere. Maybe this is what Roche is banking on - take the platform and add their own biochemistry.
      Genia seems to be claiming two advantages:
      1) Precise control over the nanopore assembly process, allowing for 'better than Poisson' distribution

      2) NanoTag biochemistry (being co-developed with Columbia and Harvard)

      Do you not think this biochemistry confers an advantage (or are you saying they don't really 'own' it due to the murky nanopore IP situation)?
      AllSeq - The Sequencing Marketplace
      [email protected]
      www.AllSeq.com

      Comment


      • #18
        Originally posted by AllSeq View Post
        Do you not think this biochemistry confers an advantage (or are you saying they don't really 'own' it due to the murky nanopore IP situation)?
        Their hardware, as much as can be judged from their patents and public presentations is elegant. Murky biochem IP is indeed the right way to characterize things. There are multiple startups, universities, and established companies working in this area, some with overlapping IP claims. It will be interesting to sit back and watch the lawyers get paid large amounts of money to argue about trivialities.

        Comment


        • #19
          Originally posted by scbaker View Post
          Very interesting. Do you know if they've purchased the IP from $LIFE or if they have any commercialization plans?
          I'm curious about this part as well. I wonder if Thermo Fisher dumped any ties with Genia after the Life acquisition?

          Comment


          • #20
            Originally posted by snetmcom View Post
            I'm curious about this part as well. I wonder if Thermo Fisher dumped any ties with Genia after the Life acquisition?
            Still haven't heard anything else about the group working on Starlight.

            As for Thermo, my assumption is they still own a portion Genia and will make a bit of money on their investment once the acquisition closes.
            AllSeq - The Sequencing Marketplace
            [email protected]
            www.AllSeq.com

            Comment

            Latest Articles

            Collapse

            • seqadmin
              Strategies for Sequencing Challenging Samples
              by seqadmin


              Despite advancements in sequencing platforms and related sample preparation technologies, certain sample types continue to present significant challenges that can compromise sequencing results. Pedro Echave, Senior Manager of the Global Business Segment at Revvity, explained that the success of a sequencing experiment ultimately depends on the amount and integrity of the nucleic acid template (RNA or DNA) obtained from a sample. “The better the quality of the nucleic acid isolated...
              03-22-2024, 06:39 AM
            • seqadmin
              Techniques and Challenges in Conservation Genomics
              by seqadmin



              The field of conservation genomics centers on applying genomics technologies in support of conservation efforts and the preservation of biodiversity. This article features interviews with two researchers who showcase their innovative work and highlight the current state and future of conservation genomics.

              Avian Conservation
              Matthew DeSaix, a recent doctoral graduate from Kristen Ruegg’s lab at The University of Colorado, shared that most of his research...
              03-08-2024, 10:41 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by seqadmin, Yesterday, 06:37 PM
            0 responses
            10 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, Yesterday, 06:07 PM
            0 responses
            9 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, 03-22-2024, 10:03 AM
            0 responses
            49 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, 03-21-2024, 07:32 AM
            0 responses
            67 views
            0 likes
            Last Post seqadmin  
            Working...
            X